Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock

Millennium Management increased its Bristol Myers Squibb stake by 5.8 million shares in Q1 2026, lifting holdings from 743,659 to 6,545,442 shares. The article is constructive on BMY’s recovery case, citing stronger-than-expected results, reiterated 2025 guidance of $46 billion-$47.5 billion in revenue and $6.05-$6.35 adjusted EPS, plus mitigation efforts ahead of Eliquis and Opdivo patent expirations. The stock remains valued at under 9x earnings with a 4.6% forward dividend yield, but patent-cliff risk keeps the tone guarded.

Analysis

Millennium’s larger BMY stake is more interesting as a signal of positioning discipline than as a standalone endorsement of the equity story. A multi-strat fund typically adds when downside is becoming more quantifiable than binary, which implies the market may be over-penalizing headline patent risk relative to the cash-flow durability of the base business. In other words, the stock may be transitioning from a “show-me” to a “mean-reversion” trade if management can keep execution tight through the next two reporting cycles.

The key second-order effect is competitive: any successful lifecycle management around Eliquis/Opdivo delays volume migration not just to generics, but to the broader class of substitute therapies and adjacent oncology/immunology competitors. That means the real battle is less about a single patent date and more about how much share erosion is accelerated by payer behavior once the market starts discounting a post-cliff earnings reset. If the company can defend pricing and sequencing through 2026, the multiple can re-rate before the full earnings impact is visible.

The setup is still asymmetric because the market is anchoring on a near-term cliff while discounting capital returns and the probability of “less bad” guidance, not outright growth. However, the risk is that the stock becomes a yield trap if management is forced to use the dividend as a credibility anchor while pipeline offsets remain too slow to matter. The thesis breaks if the next two quarters show even modest acceleration in loss of exclusivity-driven volume leakage or if the market decides the AI/cost narrative is just a margin bridge, not a durable offset.

Key Decisions for Investors

• Initiate a tactical long in BMY over the next 1-2 weeks, targeting a 3-6 month horizon; risk/reward favors a re-rating toward a low-teens multiple if management continues to de-risk the patent narrative, while downside is buffered by dividend support.
• Use BMY Jan-2027 call spreads to express upside with capped premium outlay; this is the cleanest way to play a 6-12 month multiple expansion without overexposing to an earnings miss around LOE timing.
• Pair long BMY / short a basket of higher-multiple large-cap pharma names over 3-6 months; if investors rotate toward cash-flow visibility and yield, BMY should outperform on valuation compression alone.
• Avoid chasing the move immediately after earnings; wait for either a post-print drawdown or evidence of stabilization in sell-side revisions, since the catalyst path is more about guidance durability than a single quarter beat.
• For hedged portfolios, consider selling out-of-the-money puts on BMY into weakness; implied volatility should remain elevated around patent-cliff headlines, creating attractive entry points if the market keeps overpricing binary risk.